Market research
OPL.AU Opyl Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.06
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Health Information Services
- ISIN
- AU0000070856
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.06
About
About Opyl Limited
Pathkey.AI Ltd engages in the development of digital tools that enhance healthcare experience for patients in Australia. The company offers TrialKey, an AI-driven clinical trial optimization and success prediction platform, that simulate and optimize trial designs for pharmaceuticals, medical devices, alternative therapies, and novel conditions. It also provides TrialGen, an AI-powered tool streamlines clinical trial design process for biopharma, MedTech, government, and healthcare organizations. The company was formerly known as Opyl Limited and changed its name to Pathkey.AI Ltd in August 2025. Pathkey.AI Ltd was incorporated in 1994 and is based in Milsons Point, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the OPL.AU discussion.
5 years, 5 months ago
Opyl Limited is currently in a long term uptrend where the price is trading 9.5% above its 200 day moving average.
From a valuation standpoint, the stock is 97.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.8.
Opyl Limited's total revenue rose by 32.9% to $487K since the same quarter in the previous year.
Its net income has increased by 102.6% to $22K since the same quarter in the previous year.
Finally, its free cash flow grew by 102.0% to $8K since the same quarter in the previous year.
Based on the above factors, Opyl Limited gets an overall score of 5/5.